

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

UPDATE ON THE MAJOR TRANSACTION RELATING TO THE ESTABLISHMENT AND FILING OF HANGZHOU TAIKUN EQUITY INVESTMENT FUND PARTNERSHIP (LIMITED PARTNERSHIP)

References are made to the announcement of Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”) dated July 12, 2021 and the circular of the Company dated July 23, 2021 (the “**Circular**”) regarding the entering into the Partnership Agreement in relation to the formation of the Fund. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Circular.

The Board is pleased to announce that, the Company was informed that the Fund was established on August 10, 2021 and completed the filing procedures for fund establishment with the Asset Management Association of China (the “**AMAC**”) in accordance with the applicable laws and regulations of the People's Republic of China (“**PRC**”).

Details of the Fund are set out below:

Name of Fund	Hangzhou Taikun Equity Investment Fund Partnership (Limited Partnership)* (杭州泰鯤股權投資基金合夥企業(有限合夥))
Unified Social Credit Code	91330108MA2KJKLT87
Nature	Limited Partnership
Principal Place of Business	Room 1712, 17th Floor, Block 8, No. 19 Jugong Road, Xixing Street, Binjiang District, Hangzhou City, Zhejiang Province, the PRC
General Partner	Hangzhou Tailong Venture Investment Partnership (Limited Partnership)* (杭州泰龍創業投資合夥企業(有限合夥)) (Representative: Liu Chunguang (劉春光))
Date of Establishment	August 10, 2021

Term of Business Operation	August 10, 2021 to August 9, 2041
Scope of Business	General projects: Equity investment; Venture capital (limited to investment in companies which are not listed)
Name of Manager	Hangzhou Tailong Venture Investment Partnership (Limited Partnership)* (杭州泰瓏創業投資合夥企業(有限合夥))
Name of Custodian	Bank of Hangzhou Co., Ltd.
Date of AMAC Filing	August 20, 2021
AMAC Filing No.	SSB712

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, August 23, 2021

As at the date of this announcement, the executive Directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun and Ms. Yin Zhuan; the independent non-executive Directors are Mr. Zheng Bijun, Dr. Yang Bo and Mr. Liu Kai Yu Kenneth.

* *For identification purpose only*